ANXA5 and ovarian carcinoma: Approximately three-fourths of ovarian cancer cases exhibit metastasis to the peritoneal cavity, and the TNFRSF4 fusion protein mCTH-ANXA5 is used in the treatment of metastatic ovarian cancer.